This listing of Claims will replace all prior versions, and listings, of Claims in the application:

Listing of Claims:

Claim 1 (canceled)
Claims 2-31 (previously canceled)
Claim 32 (canceled)
Claim 33 (previously canceled)

Claim 34 (new): A dosage form comprising 5 mg to 250 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, wherein (i) said dosage form provides a maximum plasma oxybutynin concentration of about .28 ng/ml to about .45 ng/ml per mg of said member in said dosage form and (ii) wherein said dosage form delivers said member from said dosage form over a period of about 24 hours.

Claim 35 (new): The dosage form according to Claim 34, wherein said salt is oxybutynin hydrochloride.

Claim 36 (new): The dosage form of Claim 35, wherein said dosage form delivers at a substantially zero order rate of release.

Claim 37 (new): The dosage form according to Claim 34, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

Claim 38 (new): The dosage form according to Claim 35, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylc llulose.

Claim 39 (new): The dosage form of Claim 34, wherein said dosage form delivers at a substantially zer order rate of release.

Claim 40 (new): The dosage form according to Claim 34, wherein said dosage form is a tablet.

Claim 41 (new): The dosage form according to Claim 35, wherein said dosage form is a tablet.

Claim 42 (new): The dosage form according to Claim 37, wherein said dosage form is a tablet.

Claim 43 (new): The dosage form according to Claim 38, wherein said dosage form is a tablet.

Claim 44 (new): A method for the management of incontinence in a patient comprising administration to a subject of a dosage form comprising 5 mg to 250 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, wherein (i) said dosage form provides a maximum plasma oxybutynin concentration of about .28 ng/ml to about .45 ng/ml per mg of said member in said dosage form and (ii) wherein said dosage form delivers said member from said dosage form over a period of about 24 hours.

Claim 45 (new): The method according to Claim 44, wherein said salt is oxybutynin hydrochloride.

Claim 46 (new): The method according to Claim 44, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

Claim 47 (new): The dosage form of Claim 44, wher in said dosage form delivers at a substantially zero order rate of release.

Claim 48 (new): The method according to Claim 45, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

Claim 49 (new): The dosage form of Claim 48, wherein said dosage form delivers at a substantially zero order rate of release.

Claim 50 (new): The method according to Claim 44, wherein said dosage form is a tablet.

Claim 51 (new): The method according to Claim 45, wherein said dosage form is a tablet.

Claim 52 (new): The method according to Claim 46, wherein said dosage form is a tablet.

Claim 53 (new): The method according to Claim 48, wherein said dosage form is a tablet.

Claim 54 (new): The method according to any one of Claims 44, 45, 46, 48, 50, 51, 52 or 53 wherein the incidence of side effects associated with oxybutynin treatment is reduced.